Today: 2 July 2026
Browse Category

NYSE:HPP 18 December 2025 - 27 February 2026

Hudson Pacific Properties (HPP) Stock on Dec. 23, 2025: Latest News, Q4 FFO Forecast, Analyst Targets, and What Investors Are Watching

Hudson Pacific Properties (HPP) Stock on Dec. 23, 2025: Latest News, Q4 FFO Forecast, Analyst Targets, and What Investors Are Watching

Hudson Pacific Properties, Inc. is ending 2025 in the middle of a classic REIT tug‑of‑war: improving company-specific balance sheet headlines versus a still-stubborn market narrative around office demand, refinancing risk, and “higher-for-longer” rate sensitivity. On Tuesday, December 23, 2025, HPP traded around the $10.5 level, up modestly from the prior session’s close after a volatile few weeks that included a reverse stock split, a major asset sale in Los Angeles, and an updated outlook for fourth-quarter funds from operations. Investing.com+1
Hudson Pacific Properties (HPP) Stock Update: Riot Games Deal, Debt Paydown, Reverse Split, and What Analysts Forecast on Dec. 18, 2025

Hudson Pacific Properties (HPP) Stock Update: Riot Games Deal, Debt Paydown, Reverse Split, and What Analysts Forecast on Dec. 18, 2025

LOS ANGELES — Hudson Pacific Properties, Inc. stock was sharply lower in Thursday trading, with shares recently around $10.31 after a steep one-day drop. The pullback lands as investors keep digesting a dense run of company headlines: a major West Los Angeles asset sale tied to Riot Games, a meaningful chunk of mortgage debt repaid, an updated fourth-quarter 2025 funds-from-operations outlook, and a 1-for-7 reverse stock split that has made “before vs. after” comparisons unusually confusing across quotes and forecasts. Los Angeles Times+2Business Wire+2
18 December 2025

Stock Market Today

  • Regencell Bioscience (RGC) Jumps 31.9%, But May Buyers Deep in the Red
    July 1, 2026, 6:50 PM EDT. Regencell Bioscience Holdings (NASDAQ:RGC) ran up 31.9% to $8.03 at the close on July 1, with volume at 13.5 times its average. But RGC is still down 60.4% from the $20.30 price in its May registered-direct deal and off 66.8% since June 1. The company brought in $20 million during that May offering and still has an at-the-market program in place, letting it tap the market for more funds. With shares trading sharply lower, raising cash will get tougher-Regencell has to sell more stock for the same payout. Monday's 2.55 million shares traded is just a sliver of the 495.47 million shares out. The big selloff shows how cautious investors are, as the Nasdaq Composite and biotech ETFs both slipped on the day.
Go toTop